Excellent analysis of the REDUCE-IT study by @matthewherper, but there's one issue that I would like to point out as well https://www.forbes.com/sites/matthewherper/2018/11/10/fish-oil-derived-drug-shows-great-promise--with-big-caveats/#35596a333291 …
Now this may be cost-effective - the composite "cardiovascular endpoint" score was derived from, among other things, death and heart attacks But it's worth noting that the medication is VERY expensive which offsets its usefulness a lot
-
-
But it's so cheap compared to every other CV drug...
-
True, but the participants were already taking statins from my understanding? So the ICER would be compared to other cardiac medications, which may prevent more events or have a similar NNT but for a shorter time-period, all on top of statins
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.